Skip to Content

Celebrex and Chemotherapy

A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced NSCLC

Objective

Patients with advanced non-small cell lung cancer whose tumor’s have high levels of COX-2 may be eligible for this study. The purpose of the study is to see if adding celecoxib versus placebo to standard chemotherapy has any benefit.

IRB Protocol Number
HIC 10-4 CALGB 30801
Principal Investigator(s)
Charles Catcher, MD

Clinical Trial Categories

  • Lung Cancer
Sponsor(s)
National Cancer Institute
Contact
Margaret White, RN OCN, CC at 603-232-8908

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000